Abstract:Objective:(CA)n repeat polymorphism in intron 1 and EGFR mutations were analyzed for its association with molecular targeted therapy responsiveness in lung cancer.Methods:Both of observed group consisted of 116 somatic specimens of lung cancer and control group consisted of 20 peripheral blood samples were analyzed by direct DNA sequencing.Epidermal growth factor receptor mutations at exons 18、19、21 were analyzed for overall 136 specimens.CA repeat polymorphisms in intron 1 of EGFR from 48 specimens were also analyzed by direct sequencing.45 lung cancer patients were followed up for their treatment outcome of molecular targeted drug(EGFR Tyrosine kinase inhibitors)molecular targeted drug.In addition,we analyzed(CA)n dinucleotide repeat polymorphism in intron 1 of EGFR followed EGFR mutations data in exons 18、19、21 for their association with clinical outcome in lung cancer patients treated with molecular targeted drug.Results:EGFR mutations were identified in 20 patients(17.25%)out of 116 somatic specimens including 17 mutations in extron domain and 3 heterozygosis in intron domain.None mutation was found in 20 peripheral blood samples in control group.Although the mutant frequency in the adenocarcinoma(21.62%)was a little higher than in the squamous cell carcinoma(8.33%)and in other histological types(11.11%)of lung cancer,there was no significant difference between them.The rate of mutations in female patients(7/36,19.45%)was a little higher than those in male patients(13/80,16.25%),but there was also no significant difference between them.Response rate to EGFR TKIs was significantly higher in the patients with EGFR mutations(62.5%)than those without mutation(0%)in observed groups(P0.01).Disease control rate to EGFR TKIs was significantly higher in the patients with EGFR mutations(100%)than those without mutation(44.4%)in observed group(P0.05).In patients harboring EGFR mutations,disease control rate to patients treated with EGFR TKls(100%)was significantly higher than those who never treated with it(40%)(P0.05).Two of three patients with heterozygosis in intron domain treated with EGFR TKls,the response rate was 0% and the disease control rate was 1/2.The frequency distribution of EGFR intron 1(CA)n repeat in 48 cases was 23(47.9%)low(CA)n repeat(CA≤16)and 25(52.1%)high ones(CA16)in cases and controls.There was no statistical correlation between the length of(CA)n repeat in intron 1 and gene mutations of EGFR(P0.05,OR﹤2).There was no significant difference in response rate and disease control rate of EGFR TKIs treatment between low and high(CA)n repeat numbers both in 16 patients with mutations and 18 patients without mutations in observed group(P0.05).Conclusion:Response rate(62.5% vs 0)and disease control rate(100% vs 44.4%)to EGFR TKIs treatment were significantly higher in the patients with EGFR mutations than who without it.Our results once again showed that somatic mutations of EGFR was a major determinant of EGFR TKIs response in lung cancer.There was no statistical correlation between the length of(CA)n repeat in intron 1 and mutations of EGFR.There was no significant difference in response rate and disease control rate of EGFR TKIs treatment between low(CA)n repeat patients and high repeat ones,cohsidering of the mutant factor.As the presents of certain disease control rate in the non-mutation lung cancer patients treated with EGFR TKls,the relationship between the length of(CA)n repeat and molecular targeted drug sensitivity need to be studied furthermore.

Intron 1 (ca)n Dinucleotide Repeat Polymorphism and Mutations of Epidermal Growth Factor Receptor and Responsiveness of Molecular Targeted Therapy in Lung Cancer

Polymorphism in Epidermal Growth Factor Receptor Intron 1 Predicts Prognosis of Patients with Esophageal Cancer after Chemoradiation and Surgery

Association of the EGFR intron 1 CA repeat length with lung cancer risk.

Mutation and Polymorphism in the EGFR-TK Domain Associated with Lung Cancer

[Clinicopathological Features Associated with EGFR Gene Mutation in Non-Small Cell Lung Cancer Patients].

Variation in the EGFR Gene is Associated with Lung Cancer

A Patient of Advanced NSCLC with a New EGFR Exon 19 Insertion Mutation and Its Response to EGFR-TKIs

EGFR Gene Mutation and Methodological Evaluation in 399 Patients with Non-small Cell Lung Cancer

EGFR Polymorphism Prediction of Radiosensitivity of Nasopharyngeal Carcinoma

Intratumoral Heterogeneity of EGFR Mutation and Clinical Significance in Chinese Patients with Advanced Non-Small Cell Lung Cancer.

Patients harboring epidermal growth factor receptor (EGFR) double mutations had a lower objective response rate than those with a single mutation in non-small cell lung cancer when treated with EGFR-tyrosine kinase inhibitors

Epidermal growth factor receptor gene and protein abnormalities in non-small cell lung cancer

EGFR with TKI-sensitive Mutations in Exon 19 is Highly Expressed and Frequently Detected in Chinese Patients with Lung Squamous Carcinoma.

Comparison of clinical outcome and efficacy of patients with advanced non-small cell lung cancer Harbouring different epidermal growth factor receptor mutations

Egfr Exon 19 Insertions: A New Family of Sensitizing Egfr Mutations in Lung Adenocarcinoma

Mutation and Expression of Multiple Treatment Response-Related Genes in a Population with Locally Advanced Non-Small Cell Lung Cancer.

Detection And Clinical Significance Of Intratumoral Egfr Mutational Heterogeneity In Chinese Patients With Advanced Non-Small Cell Lung Cancer

Polymorphisms in epidermal growth factor receptor (EGFR) and AKT1 as possible predictors of clinical outcome in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors

Clinical Outcomes of EGFR-TKI Treatment and Genetic Heterogeneity in Lung Adenocarcinoma Patients with EGFR Mutations on Exons 19 and 21

Epidermal Growth Factor Receptor Exon 20 Mutation Increased in Post-Chemotherapy Patients with Non-Small Cell Lung Cancer Detected with Patients' Blood Samples.

Analysis of epidermal growth factor receptor gene mutations in 406 small biopsy samples of lung cancer